CAPRIN-1 Autoantibody Detection for Pancreatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting pancreatic cancer are inadequate due to the lack of sensitive and early detection techniques, as existing tumor markers like CEA and CA19-9 do not elevate until the cancer is advanced, and there is a need for a simpler, more sensitive method that can be applied to both human and canine patients without imposing financial or physical burdens.
Innovation Solution
A method involving the measurement of CAPRIN-1 expression in pancreatic cancer tissues and the use of antibodies or polypeptides that react with CAPRIN-1 in blood serum samples, allowing for the detection of pancreatic cancer through antigen-antibody reactions, which includes a reagent or kit containing specific polypeptides or antibodies that bind to CAPRIN-1 proteins or nucleic acids encoding them.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional tumor markers (CEA, CA19-9) are used for pancreatic cancer detection, then the detection method is simple and widely available, but the sensitivity is insufficient and early detection is not achieved
Solution Approach 1:
The invention extracts and utilizes autoantibodies specifically produced against CAPRIN-1 protein in pancreatic cancer patients. By isolating this specific biomarker (autoantibodies against CAPRIN-1) from the complex biological system, the method achieves high detection sensitivity without requiring complex imaging equipment or procedures. The extraction of this specific autoimmune response marker resolves the contradiction between simple detection methods and high sensitivity.
Solution Approach 2:
The invention introduces CAPRIN-1 protein as an intermediary substance that mediates the detection process. The autoantibodies in patient serum react specifically with CAPRIN-1 protein, creating a measurable immune complex. This intermediary approach allows conventional serological testing methods to achieve high sensitivity by detecting the antigen-antibody reaction between CAPRIN-1 and patient autoantibodies, bridging the gap between simple methodology and high detection precision.
2Measurement precision
If advanced detection techniques with high sensitivity are employed, then early pancreatic cancer can be detected, but the financial and physical burdens on patients increase
Solution Approach 1:
The invention employs a disposable serological testing approach using CAPRIN-1 protein and autoantibody detection that can be performed on routine blood samples. Unlike expensive, complex imaging procedures requiring specialized equipment and facilities, this method uses conventional laboratory techniques that are widely available and cost-effective. The test processes biological samples (blood serum) that are easily obtained, making the high-sensitivity detection accessible without imposing significant financial or physical burdens on patients.
Solution Approach 2:
The detection method leverages the patient's own immune system response as the detection mechanism. The autoantibodies produced by the patient's body against CAPRIN-1 serve as the natural biomarker, eliminating the need for external tracers, contrast agents, or complex imaging equipment. This self-service approach allows the patient's biological system to provide the detection signal, making the process simple, non-invasive, and economically viable while maintaining high sensitivity for early cancer detection.
3Reliability
If existing tumor markers are used, then the detection method is straightforward, but the markers show normal values even in progressive cancer stages
Solution Approach 1:
The invention replaces the conventional tumor marker detection approach (which measures elevated levels of CEA, CA19-9 produced by cancer cells) with an immune-based detection system. Instead of measuring the mechanical/chemical presence of tumor markers, the method detects the immunological response (autoantibodies) generated by the patient's immune system against CAPRin-1. This substitution of detection mechanism provides superior reliability by capturing the immune system's recognition of cancer-specific antigens, which occurs earlier and more consistently than conventional marker elevation.
Solution Approach 2:
The invention changes the detection parameter from measuring tumor marker concentration (CEA, CA19-9 levels) to measuring autoantibody reactivity against CAPRIN-1 protein. This parameter change fundamentally improves detection reliability because autoantibody production occurs in response to cancer-specific antigenic changes, providing a more sensitive and accurate indicator of pancreatic cancer presence and progression. The shift in measured parameter enables reliable detection across all cancer stages without requiring complex procedural changes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the detection of pancreatic cancer with high sensitivity and specificity, potentially allowing for early diagnosis and targeted therapy, improving prognosis for both humans and animals.
Implementation Method 1
measuring a CAPRIN-1 expression in a sample separated from a subject... use of antibodies or polypeptides that react with CAPRIN-1 in blood serum samples, allowing for the detection of pancreatic cancer through antigen-antibody reactions
Data Source
AI summary
This invention relates to a method for detecting pancreatic cancer using novel tumor markers. Specifically, the invention provides a method for detecting pancreatic cancer comprising measuring the presence or an amount of a polypeptide having an reactivity of binding via an antigen-antibody reaction to an antibody against CAPRIN-1 protein in a sample separated from a subject, and to a reagent or kit for detecting pancreatic cancer comprising a CAPRIN-1 protein or a fragment thereof, an antibody against the same, or a polynucleotide encoding the same.